DIA Biosimilars 2013

EvaluatePharma

Biologic drugs market about to soar

Wednesday, June 20, 2012 11:29 AM

EvaluatePharma, a company providing pharmaceutical and biotechnology sector analysis and consensus forecasts, has released a report titled “Surveying Tomorrow’s BioPharma Landscape: The NASDAQ Biotech Index Up Close,” which shows that the quantity of biologic drugs on the market will likely soar by 2018.

More... »

Cenduit: Now with Patient Reminders

EP Clinical Trials links EudraCT and ClinicalTrials.gov

Tuesday, November 15, 2011 04:04 PM

London-based EvaluatePharma, a source for life science sector analysis, has launched its new clinical trial intelligence service, EP Clinical Trials. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information.

More... »

CRF Health – eCOA Forum

U.S. R&D productivity often undercounted, as most reports omit FDA biologics approvals

Tuesday, May 31, 2011 09:44 AM

Most reports of pharmaceutical R&D productivity undercount the number of new drugs that reach the market each year, missing out on billions of dollars of sales, because they omit approvals from the Food and Drug Administration’s (FDA) biologics division, according to a new report by London-based research company EvaluatePharma.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.